England’s NICE Takes Tough Stance On Opdivo; No Relief from Cancer Drugs Fund
Executive Summary
HTA body NICE has rejected in draft guidance the use in the NHS in England of Opdivo (nivolumab) in bladder cancer. Also, the BMS product is unlikely to gain reimbursement from the Cancer Drugs Fund for the indication because further clinical trials in bladder cancer are not ongoing. Similar issues affect the initial rejection by NICE of lenvatinib and sorafenib in advanced metastatic differentiated thyroid cancer patients.